Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial

MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta(®)). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta(®). As secondary objectives, the safety and tolerability of MSB11455 and Neulasta(®) were also compared. Healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wynne, Chris, Schwabe, Christian, Vincent, Emmanuelle, Schueler, Armin, Ryding, Janka, Ullmann, Martin, Ghori, Vishal, Kanceva, Radmila, Stahl, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183238/
https://www.ncbi.nlm.nih.gov/pubmed/32333641
http://dx.doi.org/10.1002/prp2.578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183238/
https://www.ncbi.nlm.nih.gov/pubmed/32333641
http://dx.doi.org/10.1002/prp2.578

Ejemplares similares